CMGA_PIG CHGA ELISA tesk kit
- Known as:
- CMGA_PIG CHGA Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen15614
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- CMGA_PIG CHGA ELISA tesk kit
Related genes to: CMGA_PIG CHGA ELISA tesk kit
- Gene:
- CHGA NIH gene
- Name:
- chromogranin A
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 14q32.12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-10-05
Related products to: CMGA_PIG CHGA ELISA tesk kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: CMGA_PIG CHGA ELISA tesk kit
- Inflammatory bowel disease (IBD) is a systemic disorder that affects not only the gastrointestinal tract but also extraintestinal organs and is associated with a significantly increased risk of osteoporosis. This study aims to investigate the association between plasma proteomic profiles and the subsequent risk of osteoporosis in patients with IBD. - Source: PubMed
Publication date: 2026/08/04
Yue MinYe XiaohuaJin ZhenheYe KexinXu ChengweiZhou TianyuShen Zhe - Neuroendocrine prostate cancer (NEPC) is an aggressive treatment-associated lineage state emerging with potent androgen receptor (AR) pathway inhibition. Although treatment-emergent NEPC is increasingly recognized, the transcriptional consequences of sustained AR suppression remain incompletely defined. It remains unclear to what extent AR-targeted therapies reshape cellular identity and engage neuroendocrine-associated transcriptional programs without full lineage-defining differentiation. - Source: PubMed
Publication date: 2026/07/24
Watanabe RyutaChosei MamiArai HarunaMiura NoriyoshiKikugawa TadahikoSaika Takashi - Among different types of resistant starch (RS), high-amylose maize starch serves as a representative B-type starch (B-type) sample and exhibits strong digestive resistance. However, the relationships among its structure-derived digestive resistance, microbial metabolism, intestinal epithelial stem cell activity, and barrier-related phenotypes remain unclear. In this study, common maize starch and high-amylose maize starch were used as representative A-type starch (A-type) and B-type samples, respectively. Multiscale structural characterization, in vitro digestion, fecal fermentation, 16S rRNA gene sequencing, untargeted metabolomics, and a mouse colonic organoid model were integrated. Compared with A-type, B-type showed smaller and more heterogeneous granules, a distinct crystalline structure, altered short-range order, and higher thermal transition temperatures. The hydrolysis index decreased from 98.03% in A-type to 82.14% in B-type, whereas RS content increased from 15.71% to 24.57%, together with slower hydrolysis. During in vitro fermentation, B-type reshaped the bacterial community structure and increased the relative abundances of Bifidobacterium adolescentis and Bacteroides ovatus compared with A-type. These shifts were accompanied by differences in PICRUSt2-predicted microbial functional potential and fermentation metabolite profiles, mainly involving amino acid, central carbon, and coenzyme-related metabolism. B-type fermentation supernatant produced the strongest organoid budding response, with significantly more buds than the control and A-type groups. Lgr5 and ChgA signals were also higher than in the A-type group, consistent with stronger epithelial stem-cell activity and differentiation-related phenotypes. Integrated correlation analysis and structural equation modeling showed positive associations among starch resistance, microbiota remodeling, predicted microbial functional potential, metabolite shifts, and epithelial growth- and barrier-related phenotypes. - Source: PubMed
Publication date: 2026/08/04
Zhang XuechunLi HanMa RongrongPan XiaohuaLiu ChangTian Yaoqi - Cyclin-dependent kinase 7 (CDK7) plays key roles in transcription and cell cycle regulation, and its inhibition has been proposed as a potential therapeutic strategy for hepatocellular carcinoma (HCC). The primary research objective of this study is to identify and validate CDK7-associated prognostic genes in HCC using bioinformatics approaches, construct a reliable prognostic risk model, and explore the functional role of CDK7 in HCC progression through and experiments, with a specific focus on its association with RelA/p65 phosphorylation, so as to provide evidence supporting CDK7 as a potential prognostic biomarker and therapeutic target for HCC. Two independent HCC cohorts from The Cancer Genome Atlas (TCGA)-HCC and the Gene Expression Omnibus (dataset GSE14520) were analyzed. Patients were stratified by expression. Differentially expressed genes were identified in both CDK7-based and tumor-versus-normal comparisons, and the intersection of these genes was analyzed. Univariate Cox regression and machine learning were used to screen prognostic genes and construct a risk model. The model's predictive utility was assessed using Kaplan-Meier and receiver operating characteristic (ROC) analyses. Mutation landscapes were compared between risk groups. The functional association of CDK7 was validated through and experiments. Eight prognostic genes (, , , , , , , and ) were screened from 98 intersecting genes via univariate Cox regression and least absolute shrinkage and selection operator regression analyses to construct a risk model. In the TCGA-HCC (374 HCC samples and 50 control samples) and GSE14520 cohorts (222 HCC samples and 212 control samples), patients in the high-risk group had significantly worse overall survival than those in the low-risk group (Hazard Ratio [HR] = 0.003-0.036, 95% Confidence Interval [CI] = 1.01-4.28, < 0.05). The predictive accuracy of the model was moderate, with the areas under the ROC curves (AUCs) for 1-, 3-, and 5-year survival exceeding 0.6 (specifically, 0.69 for 3-year survival). and experiments demonstrated that expression is associated with HCC proliferation, migration, invasion, and tumor growth, and this association might be related to RelA/p65 phosphorylation. This study identified a novel eight-gene prognostic signature linked to CDK7 in HCC and provided experimental evidence that CDK7 promotes tumor aggressiveness. These findings suggest the potential of CDK7 as a prognostic biomarker and therapeutic target for HCC, though further validation of its clinical utility is needed. - Source: PubMed
Publication date: 2026/07/16
Lan BinTan JieWang QingZeng Siyuan - Inflammatory bowel disease (IBD) is a relapsing inflammatory disorder of the gastrointestinal tract with increasing global incidence. Current therapies are often limited by side effects, loss of efficacy, and high cost, underscoring the need for safer and more effective alternatives, particularly multi-target agents derived from natural products. - Source: PubMed
Publication date: 2026/07/23
Bao YinAo QiangWang MengMao XiaolingZhu JunZhang MingyueChen YangZhu HongGao Jun